Login / Signup

Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction.

Rungroj KrittayaphongJirawit YadeeUnchalee Permsuwan
Published in: ClinicoEconomics and outcomes research : CEOR (2019)
This study revealed the addition of ivabradine to standard treatment to be a cost-effective treatment strategy in HFrEF patients with a heart rate ≥77 bpm.
Keyphrases
  • heart rate
  • heart failure
  • blood pressure
  • heart rate variability
  • mesenchymal stem cells